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Objectives. This study awsse4 whe(hev trcr(mvut with oral 
pre4niwue (b&s plw tapeve dma, is cxwnparnhte o lnbave. 
now metbylprednisdnne sodium succinste lsdu-M&d) therapy 
in palients with 6symylap(omntic moderate cardiac a&raft rejee- 
tiun episodes witkuut hemodynamic cumprumise. 
Backknwnd. lnlmvenous sdu.Medrol therapy is frqueutly 
mnisterc4 for m&rate reJectiw eplsocks after heart trans. 
plantation but has nut previously been ctnnpawl with an ural 
pmdniwne therapy bI nsymptomatk cprdiac mjectian in P ran. 
don&d trial. Compared with oral prednisune therapy, the 
administration of intravenous Solu-M&d is more costly aad 
twulfe intensive, and it can require lusa of work tillw for 
patients aud the family members rho accompany tlwm to treat- 
ment. 
Methods. Fortv-om heart trsnsulant uathnts with 43 epiaocka 
of asymptomatic moderate cardi~veJ&n were van&&d to 
receive 3 days of 1,ooO mg of intravenuus S&M&d (26 
tpiwd+r prfdnisonepsa bo~u~dosr 0 10omg 0rnliyror3 days, 
Triple drug immunosuppression has reduced the incidence 
and severity of cardiac rejection in heart transplant patients. 
However, rejection remains responsible for approximately 
one third of all deaths in these patients (I). A survey of 
the Working Group of Transplant Cardiologists, which in- 
cluded 24 centers, revealed that 91% of all rejections in 1989 
were asymptomatic, defined as cardiac rejection without 
hemodynamic compromise. Patients in the UCLA Cardiac 
Transplant Program have an average of 0.8 episode of 
rejection in the 1st year; 90% of these episodes are asymp 
tomatic. 
A cnurse of inlruveoous steroids is frequently used to 
treat asymptomatic cardiac rejection. However, this treat- 
ment is costly and resource intensive and ii can include loss 
of work time for patients and the family members who 
accompany them to treatment. A regimen of increased 
dosage of oral steroids is not expensive, requires no olher 
resources and also can lead to the resolution of rejection. 
Therefore, we conducted a prospective randomized trial 
to compare efficacy, complications and cost of oral pred- 
nisone therapy (b&s plus tapered doses) and intravenous 
steroid therapy in heart lransplant patients with asymptom- 
adc moderate rejection episodes. 
Methods 
Study pticnts. One hundred sixty-two heart transplant 
patients between January 1990 and June 1992 were eligible 
fur this study. Routine immunosuppressive therapy included 
triple drug therapy. consisting of cyclosporine (2 to 6 mglkg 
per day to maintain serum radioimmunoassay level between 
100 and 200 q/ml). prednisone (I mglkg per day, tapering to 
0.1 mgikg per day by 3 months after transplantation) and 
azathioprine (2 mglkg per day !o maintain white blood count 
>4,wWmm’). Patients at hiih risk for renal failure received 
3 10 6 days of OKT3 monoclonal antibody therapy immedi- 
ately after operation, with cyclosporine mannem started on 
postoperative days 2 to 4 to allow stabilization of renal 
function. 
During the study period, 58 episodes of biopsy-proved 
moderate rejection (International Society for Heart Tlans- 
planlation Scale 3A) (2) were diagnosed in 52 heart trans- 
plant patients. Fifty-three episodes of rejectiou were a%ymp 
tomatic (without clinical hemodynamic compromise). 
Spccii&lly, there were no symptoms of fahgue, shortness of 
breath or liit-headedness and no signs of hypotension 
(systolic bled pressure <IO0 mm Hg). jugular venous 
distension or third sound gallop. Of these 53 episodes, 5 
assofiated with infection and 5 associated with stemid- 
resistant rejection were excluded from randomization. 
Ra&mizatiua wotwd. The study umtocol was ao- 
proved and in acco;dance with the ho&i Human Subjack 
F’rotectioa Committee. Forty-one patients with 43 rejection 
episodes wle randomized to thempy with intravenous ste- 
roids (I p 01 methylprednisoloue &km succioate [Solu- 
Me&oil) wen intravenously over t h daily for 3 days) or 
oral prednisoue (50 mg of p~~dnisone give, orally, &ice a 
day for 3 days with a rapid daily taper to 40. 30 and 20 mg 
given orally twice a day. then decreasing by I mgldose per 
day until a twicedaily maintenance dose of IO mg orally, 
was attained). Administration of cyclosporine and azathio- 
prine was continued at the doses mentioned. If moderate 
rejection persisted. the patient would be given another 
course of steroids by the alternative method. If hemody- 
oamic instability developed or moderate rejection persisted 
despite the second course of steroids, the patient would 
receive 0KT3 monoclonal antibody therdov Wie. I). 
Folor-up. Endomyocardial biobsy &~epe&devery 2 
weeks until the rejectiou was resolved. The pathologist 
reading the biops) slides had no knowledge of the rejection 
therapy received. Infectious complications were monitored 
for the subsequent 3 months a&r therapy in the two 
randomized groups. The cost of medication, equipment and 
administration of each (ejection therapy was aualyzed. 
Statistical met&b. The Student rtest was used, with p < 
0.05 selected as significant. Data are expressed as mean 
value + I SD. 
Patient chamckris&. Forty-one heart nansplant pa- 
tients with 43 episodes of asymptomatic moderate rejection 
were randomized. Twenty episodes of reject& were ran- 
domized to intravenous stemid therapy and 23 to oral 
prednisone therapy. Patients in the int&eaouo steroid and 
oral prednisone groups did not diier with respect to age 
(54 2 13 vs. 51 + II years). gender (I8 vs. I8 men), time 
from transplantation (7.5 -c 11.3 vs. 5.4 2 9.7 monlhs), 
number of rejection episodes that were early (C6 weeks after 
transplantation) (II vs. I3 patients), number of rejection 
episodes that were the initial rejecttoo episode (16 vs. 18 
patients) and number of patients receiving OKT3 induction 
to prevent renal failure (7 vs. 6 patients). 
Cliukal ou(ron. Resolution of moderate rejection coa- 
firmed by follow-up eadomyoEardial biopsy occurred within 
4 weeks in 19 (95%) of 20 patients treated with intravenous 
steroids and 21 (91%) of 23 patients treated with oral 
prednisone balus Ad tapered d&es. There was no siguiti- 
cant difference between the two treatment groups. In rhe 
three patients whose rejection episode did not resolve with 
initial therapy, the episode was an early rejection episode. In 
all three, the episode resolved after the second course of 
corticosteroid therapy. Because none of the randoo;ized 
patients developed hemodynamic instability, OKT3 rescue 
therapy was not given in the study. 
Significant iubctious complications were defined as in- 
fections requiring intravenous antibiotic therapy or clinically 
evident viral syndromes of cytomegalovbw or herpesvirus 
occurring within 3 months of rejecdon therapy. The intrave- 
nous steroid group had two infections (herpes esophagitis, 
pseudomonas pneumonia) and the oral prednisone group had 
three infections Wscherichia co/i seosis, Klebsiello weumo- 
nia, herpes roster) (p = NS). 
Other side effects of steroid therapy were nonspecific and 
subjective, including complaints of insomnia, headaches, 
myalgias, bloating xnsation and emotiona! lability, and were 
similar in both groups. These symptoms were not quantified 
objectively but were not considered sufficiently significant o 
lhnit or modify therapy in any patient. 
to enwe adequate reversal of rejection. These factors may 
influence retrospective comparisons of ditrerent steroid reg- 
imens for the treatment of rejection. This prospective ran- 
domized trial was designed to determine whether oral ste- 
roids are in fact comparable to intravenous steroids for the 
treatment of asymptomatic moderate rejection. 
Cost of therapy. The cost of administration of intrave- 
nous steroids ranged between $lgOfor treatment in the heart 
transplant clinic to $966 for treatment in an emergency roam, 
which was necessary for patients living outside the area and 
for wekend therapy. The average cost was $563, which 
ir&ludea me of the facility, Solu-Medrol, intravenous equip- 
ment and pw:cssional services. The cost of the prednisone 
for the bolus and tapered doses wris $6.30 based on IW 
tablets dispensed. 
This study demonstrates that oral predni ,one (bolus plus 
tatwed doses) is as effective as intravenous Solo-Medrol for 
the treatment of asymptomatic msdrmte allograft rejection. 
The infectious complications at 3 months after rejection 
therapy were comparable in both treatment groups. The side 
effects of therapy such as cushingoid habitus. insomnia and 
mood swings are difficult to quantitate and were not soecif~ 
ically analyzed in this study. 
Discussion 
Costs. The cost of heart transplantation has been increas- 
ing over the past few years. The financial cost of adminis- 
tration of intravenous Solu-Medrol can vary considerably, 
depending on where the drug is administered (clinic versus 
emergency room, for example) and the number of personnel 
involved. Home administration of intravenous Solu-Medrol 
has been reported (7). but this approach also requires addi- 
tional oersonnel (home care awn&s and visitina nutinp. statlI 
Cardiac rejection accounts for 19% of early deaths and and c&s between sdoo and S?loo. The incowet&nce. c&s of 
37% of late deaths in patients who receive a heart transplant transpotition and disruption of daily routine were not quanti- 
(I). Cotticosteroid therapy remains the primary agent for fied in our study, but are also greater with intnwencus Sdu- 
reversing moderate acute. cardiac rejection. Many heart Medrol than with the oral pad&me therapy. 
transdarl centers administer intravenous Solu-Medrol. Conclusions. This studv has demonstrated that eillcacv 
tion. as previously described (3). R&entty. Wahlers et al. (4) 
I,oodmg. for 3 days to treat asymptomatic mdwde rejec: 
reported that lower doses of intraverx!s Solu-Medrol given 
fo; 3 days to treat cardiac rejection may be comparable to 
traditional higher doses. 
Oral prednismtc. Michler et al. (5) reported that reversal 
of heart transplant rejection is possible using IO0 mg of oral 
prednisone daily for 3 days. with the dose tapered over I 
week to baseline levels. Their nonrandomized retrospective 
study evaluated 85 episodes of cardiac rejection and found 
that rejection was resolved in 90% of patients with the oral 
prednisane course. Wahlers et al. (6) used an oral prednisone 
course of 50 mp: for I day, dew&w the dose to IS ma/dav 
are comparable to those associated with intravenous Solu- 
and infectious complicatiob rates of oral prednisone therapy 
Medrol therapy for asymptomatic moderate cardiac rejec- 
lion in heart transplant patients. The convenience nod lower 
cost of oral prednisone @oha plus tapered doses) may 
warrant its use for routine therapy of this type of cardiac 
rejection. As heart transplantation and other highly special- 
ized procedures once considered to be experimental now 
become standard therapy, it is appropriate to limit the 
associated costs and inconvenience to patients. 
_ . 
over 8 days in IO3 epkodes of asymptomatic moderate 
rejection and showed an 85% reversal of rejection. which 
was comparable to that for episodes of rejection treated with 
intravenous Solu-Medrol. However, their study was also 
retrospective and nonrandomized and included only patients 
treated >90 days after heart transplant surgery. 
Therapeutic decision. The choice of therapy to treat 
asymptomatic ardiac rejection may be influenced by factors 
such as cardiac hemodynamic measurements, the degree of 
lymphocytic intiltrates surrounding myocyte necrwis, the 
interval after heart transplantation and clinical findings. For 
example, the presence of a more brisk infiltrate surrounding 
myocvte necrosis on an endomvocardial bioDsv swimen or 
a ~ej&tion episode occurring within 6 week;ane; transplant 
surgery may be electively treated with intravenous Solu- 
Medrol as opposed to an oral prednisone course in an effort 
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